MedTrace Logo

Lidocaine Infusion in Pancreatic Cancer

NCT04048278 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-03-03

No results posted yet for this study

Summary

This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer.

A prospective randomized controlled double blinded trial design will be used for the proposed study.

Conditions

Interventions

DRUG

Lidocaine Hydrochloride

IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control

DRUG

Saline Solution for Injection

IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Gina E. Votta-Velis, MD PhD · Associate Professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-08
Primary Completion
2025-11-08
Completion
2026-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04048278 on ClinicalTrials.gov